BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

725 related articles for article (PubMed ID: 33205638)

  • 1. Fertility-sparing management for endometrial cancer: review of the literature.
    Garzon S; Uccella S; Zorzato PC; Bosco M; Franchi MP; Student V; Mariani A
    Minerva Med; 2021 Feb; 112(1):55-69. PubMed ID: 33205638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hysteroscopic Resection in Fertility-Sparing Surgery for Atypical Hyperplasia and Endometrial Cancer: Safety and Efficacy.
    De Marzi P; Bergamini A; Luchini S; Petrone M; Taccagni GL; Mangili G; Colombo G; Candiani M
    J Minim Invasive Gynecol; 2015; 22(7):1178-82. PubMed ID: 26092080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol.
    Zhao X; Niu J; Shi C; Liu Z
    Reprod Health; 2022 Nov; 19(1):206. PubMed ID: 36333773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study.
    Giampaolino P; Di Spiezio Sardo A; Mollo A; Raffone A; Travaglino A; Boccellino A; Zizolfi B; Insabato L; Zullo F; De Placido G; Bifulco G
    J Minim Invasive Gynecol; 2019; 26(4):648-656. PubMed ID: 30017893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial.
    Yang BY; Gulinazi Y; Du Y; Ning CC; Cheng YL; Shan WW; Luo XZ; Zhang HW; Zhu Q; Ma FH; Liu J; Sun L; Yu M; Guan J; Chen XJ
    BJOG; 2020 Jun; 127(7):848-857. PubMed ID: 31961463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reproductive and pregnancy outcomes of fertility-sparing treatments for early-stage endometrial cancer or atypical hyperplasia: A systematic review and meta-analysis.
    De Rocco S; Buca D; Oronzii L; Petrillo M; Fanfani F; Nappi L; Liberati M; D'Antonio F; Scambia G; Leombroni M; Dessole M; Lucidi A
    Eur J Obstet Gynecol Reprod Biol; 2022 Jun; 273():90-97. PubMed ID: 35526471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer.
    Falcone F; Laurelli G; Losito S; Di Napoli M; Granata V; Greggi S
    J Gynecol Oncol; 2017 Jan; 28(1):e2. PubMed ID: 27670256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.
    Chen M; Jin Y; Li Y; Bi Y; Shan Y; Pan L
    Int J Gynaecol Obstet; 2016 Jan; 132(1):34-8. PubMed ID: 26493012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
    Novikova OV; Nosov VB; Panov VA; Novikova EG; Krasnopolskaya KV; Andreeva YY; Shevchuk AS
    Gynecol Oncol; 2021 Apr; 161(1):152-159. PubMed ID: 33461741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer.
    Yang B; Xu Y; Zhu Q; Xie L; Shan W; Ning C; Xie B; Shi Y; Luo X; Zhang H; Chen X
    Gynecol Oncol; 2019 Apr; 153(1):55-62. PubMed ID: 30674421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis.
    Chae-Kim J; Garg G; Gavrilova-Jordan L; Blake LE; Kim TT; Wu Q; Hayslip CC
    Int J Gynecol Cancer; 2021 Dec; 31(12):1499-1505. PubMed ID: 34785524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
    Mitsuhashi A; Sato Y; Kiyokawa T; Koshizaka M; Hanaoka H; Shozu M
    Ann Oncol; 2016 Feb; 27(2):262-6. PubMed ID: 26578736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of obesity on the results of fertility-sparing management for atypical hyperplasia and grade 1 endometrial cancer.
    Gonthier C; Walker F; Luton D; Yazbeck C; Madelenat P; Koskas M
    Gynecol Oncol; 2014 Apr; 133(1):33-7. PubMed ID: 24680589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia.
    Harrison RF; He W; Fu S; Zhao H; Sun CC; Suidan RS; Woodard TL; Rauh-Hain JA; Westin SN; Giordano SH; Meyer LA
    Am J Obstet Gynecol; 2019 Nov; 221(5):474.e1-474.e11. PubMed ID: 31128110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women.
    Uccella S; Zorzato PC; Dababou S; Bosco M; Torella M; Braga A; Frigerio M; Gardella B; Cianci S; Laganà AS; Franchi MP; Garzon S
    Medicina (Kaunas); 2022 Sep; 58(9):. PubMed ID: 36143933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing ovarian stimulation with letrozole and levonorgestrel intrauterine system after combined fertility-sparing approach for atypical endometrial lesions: a retrospective case-control study.
    Gallo A; Di Spiezio Sardo A; Conforti A; Iorio GG; Zizolfi B; Buonfantino C; De Angelis MC; Strina I; Marrone V; Bifulco G; Alviggi C
    Reprod Biomed Online; 2024 May; 48(5):103750. PubMed ID: 38430660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients.
    Mitsuhashi A; Habu Y; Kobayashi T; Kawarai Y; Ishikawa H; Usui H; Shozu M
    J Gynecol Oncol; 2019 Nov; 30(6):e90. PubMed ID: 31576686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fertility-Sparing Treatment in Young Women with Atypical Endometrial Hyperplasia and Low-Grade Endometrial Cancer: A Tertiary Center Experience.
    Shikeli S; Gowri V; Rawahi TA
    JBRA Assist Reprod; 2020 Oct; 24(4):466-469. PubMed ID: 32569453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of women with atypical polypoid adenomyoma of the uterus: A quantitative systematic review.
    Raffone A; Travaglino A; Saccone G; Alviggi C; Mascolo M; De Placido G; Insabato L; Mollo A; Zullo F
    Acta Obstet Gynecol Scand; 2019 Jul; 98(7):842-855. PubMed ID: 30714089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fertility-sparing management of low-grade endometrial stromal sarcoma: analysis of an institutional series and review of the literature.
    Laurelli G; Falcone F; Scaffa C; Messalli EM; Del Giudice M; Losito S; Greggi S
    Eur J Obstet Gynecol Reprod Biol; 2015 Dec; 195():61-66. PubMed ID: 26476800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.